<DOC>
	<DOCNO>NCT00225797</DOCNO>
	<brief_summary>The purpose study evaluate analgesic efficacy safety oxymorphone extend release non-cancer patient chronic low back pain .</brief_summary>
	<brief_title>Efficacy Safety Oxmorphone Extended Release Chronic Non-malignant Pain</brief_title>
	<detailed_description>Patients low back pain sub-optimally responsive current analgesic treatment begin open-label treatment oxymorphone extend release ( ER ) . During Open-Label Titration Period , patient receive daily oxymorphone ER mouth ( PO ) q12h . The investigator initiate Open-Label Titration Period use study drug dose 5 mg PO q12h 2 day ; thereafter , patient continue receive 5 mg q12h titrate increment 5-10 mg q12h every 3-7 day stabilization achieve . The goal Open-Label Titration Period determine patient fix dose study medication tolerate achieves adequate analgesia . Stabilized patient randomiozed either continue current dose oxymorphone ER receive placebo total duration 12 week .</detailed_description>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Oxymorphone</mesh_term>
	<criteria>Males females 18 year age old opioid na√Øve Have initial pain intensity score least 50 mm VAS In good health determine investigator basis medical history physical examination Have moderate severe chronic nonneuropathic LBP present daily least several hour per day minimum three month prior Screening Any adjunct therapy back pain physical therapy , biofeedback therapy , acupuncture therapy herbal remedy , base patient 's current status remain unchanged period participation patient Written inform consent Pregnant and/or lactate Radiculopathy , fibromyalgia , reflex sympathetic dystrophy causalgia ( complex regional pain syndrome ) , acute spinal cord compression , cauda equina compression , acute nerve root compression , severe low extremity weakness numbness , bowel bladder dysfunction secondary cauda equina compression , diabetic amyotrophy , meningitis , discitis , back pain due secondary infection tumor Can agree stop local regional pain treatment study ( nerve/plexus block ablation , neurosurgical procedure pain control , inhalation analgesia ) . The patient must nerve/plexus block within 4 week screen Intend alter physical therapy regimen study . Surgical procedure direct towards source back pain within 6 month screen Pain secondary confirm suspected neoplasm Dysphagia difficulty swallow tablet capsule , inability take oral medication Significant prior history substance abuse alcohol abuse Use investigational medication within 30 day prior first dose study medication Previous exposure oxymorphone History clinically significant intolerance oxymorphone know hypersensitivity opioid analgesic History seizure Ileostomy colostomy Use MAO inhibitor within 14 day prior start study medication Other clinically significant condition judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>chronic pain</keyword>
	<keyword>low back</keyword>
	<keyword>opioid</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>